• Barry MP, Austin EJ, Bhatraju EP, Glick SN, Stekler JD, Tung EL, Hansen RN, Williams EC, Gojic AJ, Pickering EI, Tsui JI. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. Harm reduction journal. 2022 Nov 1; 19(1):121.
• Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics: A Randomized Clinical Trial. JAMA Network Open. 2022 Oct 3; 5(10):e2236904.
• Davy-Mendez T, Sarovar V, Levine-Hall T, Lea AN, Sterling SA, Chi FW, Palzes VA, Luu MN, Flamm JA, Hare CB, Williams EC, Bryant KJ, Weisner CM, Silverberg MJ, Satre DD. Characterizing Unhealthy Alcohol Use Patterns and Their Association with Alcohol Use Reduction and Alcohol Use Disorder During Follow-Up in HIV Care. AIDS and behavior. 2022 Sep 28.
• Edwards GG, Miyashita-Ochoa A, Castillo EG, Goodman-Meza D, Kalofonos I, Landovitz RJ, Leibowitz AA, Pulsipher C, El Sayed E, Shoptaw S, Shover CL, Tabajonda M, Yang YS, Harawa NT. Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS and behavior. 2023 Jan 1; 27(1):10-24.
• Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS (London, England). 2022 Oct 1; 36(12):1689-1696.

» View more Citations

• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• Evidence Review Identifies Modest Mortality Disparities among Racial and Ethnic Minority Groups in VA Healthcare
  To support VA’s efforts to better understand the scale and determinants of disparities in racial and ethnic mortality – and to develop interventions to reduce disparities, investigators from the VA Evidence-based Synthesis Program (ESP) Coordinating Center in Portland, OR conducted an evidence review of mortality disparities specific to VA. Findings showed that although VA’s equal access healthcar...
  
  Date: March 1, 2018
• Racial Disparities in HIV Quality of Care that May Extend to Common Comorbid Conditions
  To more fully understand patterns of racial disparities in the quality of care for persons with HIV infection, this study examined a national cohort of Veterans in care for HIV in the VA healthcare system during 2013. Findings showed that racial disparities were identified in quality of care specific to HIV infection – and in the care of common comorbid conditions. Blacks were less likely than whi...
  
  Date: September 22, 2016
• New Guidelines May Significantly Decrease Cost for Testing Immune Function in Veterans with HIV
  In 2012, the Department of Health and Human Services recommended CD4 testing in patients with HIV every 3 to 6 months – except in patients with consistently suppressed virus and sustained CD4 cell count, who could be tested every 6 to 12 months. In 2014, updated guidelines recommended that in individuals with viral suppression, CD4 testing be considered either optional or annual, depending on the ...
  
  Date: July 1, 2016
• Consequences of Notifying VA Patients about Potential Exposure to Large-Scale Adverse Events
  This study sought to determine the intended and unintended consequences of patient notification following a large-scale adverse event (LSAE) within the VA healthcare system, which systematically looks for LSAEs, tracks potentially exposed patients, and communicates with them after LSAE notification. Findings showed that more than two-thirds of potentially exposed patients returned for HCV, HBV, an...
  
  Date: May 1, 2015

» View more Publication Briefs

» View more Studies

• Telehealth Collaborative Care for Veterans with HIV Living in Rural Settings || In Progress

  Collaborative Care for Veterans with HIV Living in Rural Settings Feature Article...largest provider of care for persons with HIV in the U.S., with more than 26,000 Veterans

• AppendixIV-EvidenceTables.xls

  DIABETES &LDRAFT VA-ESP&C&P of &N&R&D 5. HIV HCV Author, Year Title Aims Study design...diagnostic and therapeutic care for HIV-infected individuals with PCP. Retrospective

• pharmacotherapy-sud.pdf

  ...disorder, or human immunodeficiency virus (HIV) status. There was insufficient evidence...HAM-D Hamilton Depression Rating Scale HIV Human immunodeficiency virus hr Hour

• VA Video Connect to Improve Access to Multi-disciplinary Specialty Care || In Progress

  ...the effectiveness of multidisciplinary HIV care delivered via VA Video Connect...Treatment of complex conditions like HIV requires multidisciplinary care and

• HSR&D Impacts

  ...data on HIV care The VA is the single largest provider of care to HIV-infected...about HIV. This study used 1993 and 1994 data from VA's national HIV Registry

» View more Publications

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the HIV/AIDs information section of the VA's Office of Public Health website.
• Visit the Centers for Disease Control & Prevention HIV information section.
• Learn more about all VA research related to HIV on the VA Office of Research & Development’s infectious disease topic page.